Upstart sets off on a clinical journey, looking to make a name for its 2nd-gen CB1 blockers

John Carroll

Editor & Founder

A small Montreal-based biotech out to make a name for itself as a second-gen developer of CB1 receptor blockers has successfully gathered $35 million for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Upstart sets off on a clinical journey, looking to make a name for its 2nd-gen CB1 blockers

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­start sets off on a clin­i­cal jour­ney, look­ing to make a name for its 2nd-gen CB1 block­ers

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Upstart sets off on a clinical journey, looking to make a name for its 2nd-gen CB1 blockers